Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of fenretinide in treating patients who have
recurrent or metastatic ovarian epithelial or primary peritoneal cancer. Drugs used in
chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing